Supplementary Figure S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Absence of PARP inhibitor efficacy in IDH1mut, ARID1Amut, or BAP1mut CCA_PDXs. (A) Dose-response curves of niraparib for a panel of tumoroids derived from CCA_PDXs. Cell viability was determined using Cell Titer-Glo assay 7 days after the treatment initiation. Data are mean ± s.d. from independent biological replicates. PDX41, n=3; PDX78, n=3; PDX85, n=6; PDX75, n=2; PDX75.2, n=2; PDX118, n=3; PDX133, n=3. (B) Half-maximal inhibitory concentration (IC50) of niraparib in tumoroids derived from CCA_PDXs. (C) Representative images of immunohistochemical staining for a cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX85 cells treated as for Fig 4C. (D) Representative images of immunohistochemical staining for cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX78 treated as for Fig 4D. Scale bar, 250 µm.